Background: Clinical information about bacteremia due to extended-spectrum b-lactamase (ESBL)-producing pathogens in cancer patients was limited. The study was aimed to identify the clinical manifestations and risk factors for mortality in ESBL-producer bacteremia in cancer patients. Methods: A retrospective study of bacteremia caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae in adults with cancer in National Cheng Kung University Hospital and National Taiwan University Hospital from July 2002 to August 2007 was conducted. Clinical characteristics, initial manifestations, and antimicrobial therapy were analyzed for their association with crude mortality at 14 days after bacteremia onset. Results: A total 113 episodes of bacteremia caused by E coli (59.3%), K pneumoniae (39.8%) or both (0.9%) were included. Patients with hematological malignancy were younger (55 AE 22 vs. 69 AE 14 years, p < 0.003) and had less co-morbidity, but were more likely to have neutropenia (73.1% vs. 4.6%, p < 0.001) than those with solid tumor. By the univariate analysis in 113 * Corresponding author. Division of Infectious Disease, Department of Internal Medicine, National Cheng Kung University Hospital, No. 138, Sheng Li Rd., Tainan 704, Taiwan.
Introduction
Although many potent and broad-spectrum antibiotics had been marketed in the past decades, bacterial infections still caused substantial mortality and morbidity among cancer patients with or without neutropenia. This may be related to more immunosuppressant medications and aggressive diagnostic or therapeutic tools in clinical management of various cancers. Gram-positive bacteria were predominant causative pathogens of bloodstream infections in cancer patients in western countries, 1 but Gram-negative bacilli could cause severe sepsis and mortality. Enterobacteriaceae, especially Escherichia coli and Klebsiella pneumoniae, remain the prevalent causes of bacterial infections in cancer patients. 2e5 Extended-spectrum b-lactamase (ESBL)-producing pathogens were considered to be related to a poor outcome. 6 The recognized risk factors for acquisition of ESBL-producing pathogens included previous antibiotics use, longer hospital stay, and intravascular devices, which were also characteristic in cancer patients. 7e9 Besides, the trend of increasing ESBL-producer bacteremia has been a great concern due to increasing medical expenditure and mortality. 6 Variable severity and outcome were observed in individuals with ESBL-producer bacteremia. There were few studies discussing in ESBL-producing bacteremia in cancer patients so far. 10, 11 We are intended to identify clinical features and risk factors for the mortality in cancer patients with ESBL-producer bacteremia.
Methods
The retrospective cohort study was conducted at National Cheng Kung University Hospital and National Taiwan University Hospital in Taiwan, two medical centers with 1,100 and 2,000 beds, respectively. The study period was May 2002 through August 2007. All eligible patients were identified retrospectively through the records of clinical microbiology laboratory at both centers, where ESBL production was detected by the screening and then phenotypic confirmatory tests according to those recommended by the Clinical and Laboratory Standards Institute (CLSI). 12 Patients older than 18 years who had underlying malignancy and ESBL-producing E coli or K pneumoniae bacteremia were included. Growth of the same organism in blood cultures after at least 4 weeks from the initial bacteremia episode was considered to be a new infectious episode. The primary outcome in the study is the 14-day crude mortality rate, and crude mortality rate is defined as the rate of all death after bacteremia onset.
Data collection
Retrieved from medical chart records was clinical information, including sex, age, classification of malignancy type, clinical manifestations, co-morbidity, primary site of infection, serum biochemistry, laboratory data, antimicrobial therapy, and clinical outcome. Besides, host factors regarded as being immunosuppressive, such as systemic steroid, immunosuppressant therapy, neutropenia status, were also recorded.
Definitions
Hematological malignancies referred to the types of cancer that affect blood, bone marrow, and lymph nodes, and solid tumors were malignant tumors that develop in virtually any tissue or organ. ESBL-producer bacteremia is the bacteremic episode due to E coli or K pneumoniae with ESBL production phenotypically detected according to the CLSI criteria. 12 Breakthrough bacteremia was defined as the development of bacteremia caused by the same ESBL-producer while at least one in vitro active antimicrobial agent has been used for at least 5 days. Recent immunosuppressant therapy included corticosteroid use (10 mg or an equivalent dosage daily dosage) for more than 2 weeks, and chemotherapy or anti-rejected therapy within 4 weeks before bacteremia onset. Neutropenia was defined as absolute neutrophil counts less than 500/mm 3 at the bacteremia onset. Pitt bacteremia score was measured at the bacteremia onset to evaluate the severity of bacteremia. 13 Extreme body temperature (BT) indicates BT below 36 C or more than 39 C. Organ dysfunction was defined according to organ dysfunctions and/or infection model, and categorized as respiratory, cardiovascular, renal, neurologic, hepatic, or hematological failure.
14 Severe sepsis means sepsis associated with organ dysfunction, hypoperfusion, or hypotension which could be reversed after adequate fluid resuscitation. 15 The date of the first positive blood culture was regarded as the date of bacteremia onset. Antibiotic therapy was considered to be appropriate, if the prescribed antibiotic was in vitro active against the causative organism. Antibiotic b-lactamase producer in cancer patientstherapy was classified as empirical or definitive therapy. The former was defined as antimicrobial agents given before the susceptibility result was available, and the latter as antimicrobial agent adjusted after the susceptibility data are available.
Statistical analysis
All statistical data were analyzed with SPSS software, version 13.0 for Windows (SPSS Inc, Chicago, IL, USA). Continuous variables were compared by Student t test while categorical variables were compared by c 2 test or two-tail Fisher's exact test. The p values <0.05 were considered to be statistically significant. Variables considered significant in univariate analysis were the candidates included in multivariate analysis. Logistic regression analysis was used to identify the independent risk variables for mortality. The KaplaneMeier method was used for the survival analysis.
Results

Study population
A total of 113 (32.2%) episodes of ESBL-producer bacteremia in patients with underlying malignancy were identified among 351 episodes of bacteremia due to ESBL-producing E coli and K pneumoniae during the study period. Clinical characters of 113 episodes among 110 patients were shown in Table 1 . There were two major types of malignancy. Hematological malignancy included leukemia or lymphoma, and solid tumors a variety of malignancies, such as lung, colon, liver, breast, gastric, or bile duct cancer. Twenty-six (23%) episodes occurred in patients with hematological malignancy and 87 (77%) episodes solid tumors. Their mean age among them was 65 AE 18 years. Patients with hematological malignancy were younger than those with solid tumor (53 vs. 68 years respectively, p Z 0.003). Neutropenia was present in 20.4% of all patients, and 82.6% occurred in patients with hematological malignancy. Although co-morbidities, including diabetes mellitus (0% vs. 29.9%, p < 0.001), chronic kidney disease (0% vs.18.4%, pZ0.021), or liver cirrhosis (0% vs. 18.4%, p Z 0.021), were less often noted in patients with hematological malignancy, more immunosuppressant therapy, such as chemotherapy (84.6% vs. 18.4%, p < 0.001) and steroid (30.8% vs. 10.3%, p Z 0.024) was recently used in these patients. The severity of bacteremia, as indicated by severe sepsis (p Z 0.45) or Pitt bacteremia score (!4 points, p Z 1.0) did not vary significantly between two patient groups.
Empirical carbapenem therapy was prescribed more often to patients with hematological malignancy than those with solid tumors (53.8% vs. 32.2%, p Z 0.064). Administration of appropriate empirical therapy was more frequent in patients with hematological malignancy, though the difference is not statistically significant (57.7% vs. 40.2%,p Z 0.123).
Mortality and predictors of outcome
Of 113 episodes, 27 (24%) episodes died within 14 days after onset of bacteremia. The mortality rate of ESBL-producing E coli was 19.4% and K pneumoniae was 28.8% (p Z 0.26). The primary outcome, 14-day mortality rate, of those with solid tumors, tended to be higher than that of hematological malignancy (37.6% vs. 11.5%, p Z 0.12). Of 79 monomicrobial bacteremic episodes, 20 (25.3%) died within 14 days, and 7 (20.6%) of 34 polymicrobial episodes did (p Z 0.064) ( Table 2) .
By the univariate analysis, factors associated with 14-day mortality among ESBL-producer bacteremia were pneumonia, urosepsis, skin and soft-tissue infection, respiratory failure, shock, extreme BT, severe sepsis, higher Pitt bacteremia score, appropriate definitive therapy, and carbapenem use ( Table 2 ). The presence of inappropriate empirical therapy, polymicrobial bacteremia, fluoroquinolone (levofloxacin, ciprofloxacin, or lomefloxacin) resistance, had no impact on mortality. Multivariate analysis with a logistic regression model found some independent factors positively associated with mortality, including clinical presentations with severe sepsis [adjusted odds ratio (AOR), 24.3; 95% confident interval (CI), 5.6e105.0; p < 0.001] and pneumonia (AOR, 5.2; 95% CI, 1.3e21.0; p Z 0.021). The receipt of appropriate definitive therapy was negatively associated with mortality (AOR, 0.1; 95% CI, 0.01e0.6; p Z 0.011) ( Table 3 ). The survival curve plotted by KaplaneMeier method did not showed a survival benefit among those with appropriate versus inappropriate empirical therapy (p Z 0.93, Fig. 1A ). However, there is a higher survival rate in patients with appropriate definitive therapy than those with inappropriate definitive therapy (p < 0.001, Fig. 1B ).
Discussion
Since human pathogens with ESBL production were identified in 1983, they had been found to distribute globally, 7 and their clinical threat was increasing emphasized due to multiple drug resistance and their adverse impact of mortality. 9, 10 Specific clinical information of ESBL-producer bacteremia in cancer patients is limited. 10, 11 Neutropenia and recent immunosuppressant with steroid or chemotherapy have been reported as host factors associated with increasing mortality in the cases of bacteremia, 10, 11 and not surprisingly these factors or conditions were more prevalent in patients with hematological malignancy. In accordance with the finding that Gudiol et al. has demonstrated that solid tumors as underlying disease wound influence the mortality rate in ESBL-producing E coli bacteremia, 10 mortality rates, irrespective of sepsisrelated or crude mortality rates at 14 or 30 days after bacteremia onset, there was a trend that patients with solid tumors had a worse prognosis than those with hematological malignancy. Younger age and less co-existing chronic illness in individuals with hematological malignancy were the possible reasons for such a finding. Another relevant issue is that according to IDSA guideline, more broad-spectrum b-lactam drugs would be prescribed for febrile neutropenic cancer patients, 3 and this clinical practice promoted more and early use of carbapenems. A carbapenem was used in 91% of neutropenic patients and 70% of non-neutropenic patients (p Z 0.04), and definitive antimicrobial therapy was earlier shifted to appropriate therapy among neutropenic patients than non-neutropenic patients (1.9 vs. 2.2 days; p Z 0.025). Therefore neutropenia, although well known for predisposing to bacterial infections in cancer patients, was commonly noted in patients with hematological malignancy, but did not result in a poor outcome.
In concordance with several published reports that mortality rate in ESBL-producing E coli or K pneumoniae bacteremia was about 16e42%, 10,11,16e19 the mortality rate in the present study was 24%. Three independent prognostic factors in our study were pneumonia as the source of bacteremia, severe sepsis, and the use of drugs other than carbapenem as definitive therapy. The former two factors were difficult to be amendable, but the prescription of in time and appropriate antimicrobial therapy, according to the in vitro susceptibility results from the clinical microbiology laboratory, can improve the short-term outcome of cancer patients with ESBL-producer bacteremia. Although the emergence of fluoroquinolone resistance has been a concern as an independent prognostic factor in E coli and K pneumoniae infections, 11, 20 the causative isolates in the present study exhibited a high extent of fluoroquinolone resistance (82%). However, fluoroquinolone resistance had no significant impact on mortality in the study.
As for the source of E coli and K pneumonia bacteremia, some studies revealed intra-abdominal infections heralded a poor prognosis in affected patients. 16, 17 In accordance with a recently proposed score for the prediction of early death in adults with cancer and bloodstream infections which highlighted the clinical significance in presence of pulmonary infiltrates, 21 pneumonia as the potential source of bacteremia, especially the presence of respiratory failure, independently signified a grave outcome, and may justify the (14) 12 (14) 4 (15) 1.000 Chronic kidney disease 16 (14) 11 (13) early use of carbapenems for the life-threatening infections caused by ESBL-producing Enterobacteriaceae.
Many studies evaluated the role of appropriateness antimicrobial therapy in the outcome analysis and emphasized the importance of appropriate empirical therapy. 5, 16, 17 However, our study noted that initial inappropriate therapy was not related to a grave outcome when compared with initial appropriate therapy. However, it is important to adjust antimicrobial therapy according to susceptibility results, as echoed in two studies. 10, 17 Appropriate definitive therapy for ESBL-producer bacteremia would be beneficial, as evidenced in the present study.
In summary, the presence of neutropenia or the underlying hematological malignancy in cancer patients with ESBL-producer bacteremia was not significantly associated with an increase in the mortality rate. Appropriate definitive antimicrobial therapy will be beneficial in improving clinical outcome. b-lactamase producer in cancer patients
